Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:35:28 EST Sat 10 Jan 2026
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q0.52.66·2.700.42.70+0.3514.912,741.731,53529,6012.62  2.75  2.5056.89  0.556219:58:0507:0015 min RT 2¢

Recent Trades - Last 10 of 29601
Time ETExPriceChangeVolume
19:58:05Q2.670.32100
19:56:25Q2.66030.31031,111
19:54:35Q2.66360.313624
19:53:42Q2.66030.3103400
19:53:42Q2.66020.310250
19:51:53Q2.66480.314810
19:51:39Q2.66020.31026
19:51:34Q2.660.31150
19:51:23Q2.670.3225
19:51:04Q2.670.3250

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-09 07:00U:IBIONews ReleaseiBio Announces $26 Million Private Placement
2025-11-24 16:15U:IBIONews ReleaseiBio to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-12 16:01U:IBIONews ReleaseiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-10-30 07:00U:IBIONews ReleaseiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
2025-10-23 07:00U:IBIONews ReleaseiBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-21 07:00U:IBIONews ReleaseiBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek(TM) and PEGS Europe 2025
2025-09-05 07:30U:IBIONews ReleaseiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
2025-08-25 07:00U:IBIONews ReleaseiBio Announces Closing of $50 Million Public Offering
2025-08-19 08:01U:IBIONews ReleaseiBio Announces Pricing of $50 Million Public Offering
2025-08-18 16:01U:IBIONews ReleaseiBio Announces Proposed Public Offering
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
2025-06-23 16:15U:IBIONews ReleaseiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
2025-06-16 07:00U:IBIONews ReleaseiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction
2025-04-22 08:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
2025-04-07 07:00U:IBIONews ReleaseiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
2025-02-19 16:05U:IBIONews ReleaseiBio to Begin Trading on the Nasdaq Stock Exchange
2025-02-10 16:05U:IBIONews ReleaseiBio Reports Fiscal Second Quarter 2025 Financial Results